ANI Pharmaceuticals heads into its third-quarter report with a credibility question rather than a demand question. The company posted a record second quarter, yet it also delivered the first cut of the year to its forecast for Cortrophin, the corticotropin gel that drives most of its growth story. That shift, after three straight calls of reaffirming or raising, left the stock looking for proof that the reduced target is a floor and not a first step down.

Wall Street expects earnings of $1.80 per share on revenue of $280.2 million. That would mean revenue growth of about 23% from a year ago but earnings growth of under 10%, a gap that captures the margin story well. ANI is growing quickly, but more of that growth is coming from lower-margin mix. Gross margin slipped roughly 230 basis points year over year to 62.6% last quarter, and management guided third-quarter adjusted EBITDA lower sequentially, so the slight dip in expected EPS from the prior quarter's $1.82 is by design rather than a sign of trouble. For the full year, management reaffirmed revenue of $1.08 billion to $1.14 billion and adjusted EPS of $9.19 to $9.69. The Street's $1.11 billion revenue estimate sits at the midpoint, but its $9.22 EPS forecast hugs the bottom of the range, which suggests analysts accept the top line but doubt how much profit leverage will come with it.

The number that matters most is Cortrophin. Management lowered its full-year outlook to $520 million to $540 million from $540 million to $575 million, mainly to reflect first-half results, and set a third-quarter range of $143 million to $153 million. Simple arithmetic shows the problem. After roughly $192 million in the first half, hitting even the low end of the annual guide requires about $175 million or more in the fourth quarter. A third-quarter result near the top of the range would make that step-up look plausible. A result at or below the bottom would put the annual target at risk and probably revive the debate over why strong public prescription data have not turned into equally strong reported revenue, a gap analysts raised on two straight calls and management could not fully explain.

The gout expansion is where the back-half bet rests. ANI increased its sales force by about half, to roughly 180 reps, and the team was fully deployed by the end of June. Early signs were encouraging, with nearly all new reps generating multiple cases and more than a third of prescribers starting two or more patients. July was also the best month yet for new cases in established specialties. The catch is that gout patients use fewer vials and bring in less revenue per patient, so case growth may convert to dollars more slowly than headline demand suggests. Clear commentary on new patient starts, refill persistence and revenue per patient would do more to steady the story than any single quarter's revenue figure. Investors should also look for the promised recovery at Alluvion, whose sales fell 16% last quarter under a back-half-weighted guide, and for progress toward 15 generic launches after 12 through midyear.

The market has already priced in some skepticism. Shares have fallen 7.7% since the last report while the S&P 500 was roughly flat, and at $71.17 the stock sits below its 200-day moving average of $77.82, near the low of its post-earnings range and below the floor of the prior quarter's trading band. Sentiment is still bearish, though slightly less so than before the last report, which hints that some selling pressure may have run its course.

In the end, this report will be judged on whether Cortrophin lands comfortably inside its third-quarter range and whether management can explain how gout uptake bridges the steep path into the fourth quarter. If both happen, the reaffirmed full-year targets regain credibility. If not, a second cut becomes the next worry.